Agenda Overview –

– Evidence and Health Technology Assesment – Terms, Concepts, and Landscape

– What Is Cost-Effectiveness

– Methods of Cost-Effectiveness Analysis

– Opportunities and Risks of Cost-Effectiveness Data

– Cost-Effectiveness in Different Product Types and Therapeutic Categories

– Policy Makers and Cost-Effectiveness Around the World

– Panel Discussion: Strategic, Tactical, and Business Considerations

– Internal Resources

– Case Study: Using Cost-Effectiveness Data in a Coverage Decision

– Case Study: Percutaneous Heart Assist

– Case Study: Deep Brain Stimulation

– Case Study: The Drug-Eluting Stent

– General Discussion

Speakers –

– Parashar Patel, Vice President, Health Economics and Reimbursement, Boston Scientific

– Gregory de Lissovoy, Senior Research Scientist, Vice President of Health Technology, United BioSource

– John Hermandez, Vice President, Neuromodulation, Health Economics and Reimbursement, Boston Scientific

– Bonnie Handke, Senior Director, Neuromodulation Reimbursement, Medtronic

– William Sarraille, Partner, Sidley Austin

– Thomas Goss, Vice President, Boston Healthcare Associates

– Liesl Cooper, VP, Global Healthcare Economics, Policy & Reimbursement, Medical Devices, Covidien

– Richard Toselli, Worldwide VP of Clinical Evidence & External Relations, DePuy Spine, a J&J Company

– Ramy Mahmoud, Chief Medical Officer, World Wide Vice President, Evidence Based Medicine, Ethicon, Inc.

– Andrew Greenfield, VP, Healthcare Solutions, Abiomed, Inc.